- Details
- Maha Hussain is discussing the BRCAAway with Alicia Morgans, based upon Dr Hussain's presentation at ASCO 2022. The BRCAAway Trial is a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with mCRPC with DNA repair defects either in the tumor or germline. The PARP-inhibitor olaparib is approved for mCRPC patients with deleterious germline or somatic homologous...
|
- Details
- Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation sequencing...
|
- Details
- Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospit...
|
- Details
- Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...
|
- Details
- In this LUGPA CME presentation, Dr Emmanuel Antonarakis discussed genomic profiling, germline, and somatic testing in the landscape of prostate cancer. He discusses what are germline mutations, what are somatic mutations, how common they are in prostate cancer as well as who should be tested for these mutations. Dr. Antonarakis guides the views through a genomics report, a next-generation sequenci...
|
- Details
- Reconsidering back-to-back AR-directed therapies: An interview with Maha Hussain, co-principal investigator of the PROfound study. Precision medicine and targeted therapy are possible in prostate cancer. Unmet needs have included more focused treatment and novel modes of action to counter resistance to hormonal and cytotoxic therapies. The PROfound study of the PARP inhibitor olaparib in heavily p...
|
- Details
- Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...
|
- Details
- Panagiotis Vlachostergios, MD, PhD, joins Alicia Morgans, MD, MPH, to discuss germline and somatic genetic testing and the ways in which genomic material can be integrated into clinical practice. Dr. Morgans and Dr. Vlachostergios agree that patients with metastatic disease, among others, should undergo germline genetic testing, and describe how genetic counselors can help patients make sense of g...
|
- Details
- Ken Pienta, MD, discusses the role of prostate-specific membrane antigen (PSMA) in facilitating personalized medicine as an imaging agent and selection tool for assigning patients to targeted therapy. He mentions the myriad of trials on PSMA radio-ligand therapeutics that have validated its effect in patients for metastatic prostate cancer. James Gulley, MD, Ph.D., FACS, gives an overview of genom...
|
